Illumina
Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina has developed a line of DNA sequencing technology products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests.
Illumina Company Profile
President & CEO: Francis deSouza
CEO photo:
Website: www.illumina.com
Ticker symbol: ILMN
Headquarters: San Diego, CA
Illumina employees: 5,500+ globally
Revenues: $2.4 Billion USD in 2016
Founded: 1998
Founders: Larry Bock, Anthony Czarnik, David Walt, Mark Chee, John Stuelpnagel
Illumina News
All children and adolescents with cancer in Ireland, including those who relapse following treatment, will be offered enrollment in the project.
The organizations launched the clinical trial to assess clinical utility of whole-genome sequencing in cardiovascular disease care.
Avitia Launches With C$5M in Seed Financing to Advance Molecular Testing Platform
The platform will enable on-site molecular profiling of liquid biopsy samples for cancer patient monitoring and treatment response prediction.
Illumina to Incorporate Myriad's Genomic Instability Score Into Updated TSO 500 Cancer Assay
GIS measures DNA repair defects via loss of heterozygosity, large-scale state transition, and telomere allele imbalance.
Cancer Study Sees Tailored Treatment, Outcome Boost with Comprehensive Genomic Profiling
Investigators tracked clinical and treatment outcomes for advanced cancer patients who had tumor testing with an in-house assay developed by Providence Health.